Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
Public ClinicalTrials.gov record NCT01401959. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The investigators propose to evaluate eribulin as adjuvant therapy in breast cancer patients who have residual invasive disease in breast or lymph node tissue following standard neoadjuvant chemotherapy and surgery regimen. Three cohorts of patients will be evaluated separately based on tumor type: triple-negative, hormone-receptor-positive/HER2-negative, and HER2-positive breast cancers.
Study identification
- NCT ID
- NCT01401959
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 127 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2011 (Actual)
- Primary completion
- Apr 3, 2017 (Actual)
- Completion
- Apr 3, 2017 (Actual)
- Last update posted
- Jun 15, 2018
2011 – 2017
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists North | Fort Myers | Florida | 33916 | — |
| Florida Cancer Specialists South | Fort Myers | Florida | 33916 | — |
| Watson Clinic Center for Cancer Care and Research | Lakeland | Florida | 33805 | — |
| Florida Hospital Cancer Insitute | Orlando | Florida | 32804 | — |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | — |
| Providence Medical Group | Terre Haute | Indiana | 47802 | — |
| Mercy Hospital | Portland | Maine | 04101 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| National Capital Clinical Research Consortium | Bethesda | Maryland | 20817 | — |
| Nebraska Methodist Cancer Center | Omaha | Nebraska | 68114 | — |
| Atlantic Health System | Morristown | New Jersey | 07960 | — |
| Hematology Oncology Associates of Northern NJ | Morristown | New Jersey | 07960 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| South Carolina Oncology Associates | Columbia | South Carolina | 29210 | — |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Health Physician Group | Arlington | Texas | 76011 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01401959, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 15, 2018 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01401959 live on ClinicalTrials.gov.